Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Encephalopathy in ifosfamide-treated patients.

O Merimsky1, I Reider-Groswasser, N Wigler

  • 1Department of Oncology, Ichilov Hospital, Sourasky Medical Center, Tel-Aviv University, Israel.

Acta Neurologica Scandinavica
|November 1, 1992
PubMed
Summary

Ifosfamide and mesna can cause acute encephalopathy in cancer patients, presenting with neurological symptoms. This serious side effect, observed in 17.8% of patients, requires careful monitoring during chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.

ESMO open·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Ifosfamide is a chemotherapy agent used for various cancers.
  • Mesna is often co-administered to mitigate urotoxicity.
  • Acute encephalopathy is a rare but severe neurological complication.

Purpose of the Study:

  • To report the incidence and clinical characteristics of acute encephalopathy associated with ifosfamide and mesna treatment.
  • To describe the neurological manifestations and outcomes in affected patients.

Main Methods:

  • Retrospective analysis of 28 patients with advanced solid tumors or lymphomas treated with ifosfamide and mesna.
  • Clinical data collection on neurological symptoms, timing of onset, and patient outcomes.
  • Review of neuroimaging (Brain CT) and laboratory findings.

Related Experiment Videos

Main Results:

  • Five out of 28 patients (17.8%) developed acute encephalopathy.
  • Symptoms included altered mental status, seizures, and psychiatric manifestations, appearing 2-7 days post-treatment.
  • Three patients experienced fatal outcomes; two recovered fully. Associated findings included myelosuppression, renal failure, and electrolyte imbalances.

Conclusions:

  • Acute encephalopathy is a significant potential neurotoxicity of ifosfamide and mesna treatment.
  • Prompt recognition and management are crucial due to potential severity and fatality.
  • Further research into the underlying mechanisms and preventative strategies is warranted.